Treatment of superficial benign vascular tumors by high intensity focused ultrasound: Observations in two illustrative cases

Jacek Calik, Tomasz Zawada, Torsten Bove, Jacek Calik, Tomasz Zawada, Torsten Bove

Abstract

Background: Existing therapeutic methods for reduction or removal of superficial vascular malformations and tumors have high risks of scarring and other complications that result in aesthetic appearance less favorable than the baseline. Patients are often cautioned against intervention, which can lead to psychosocial problems and low self-esteem. Improved treatment modalities are therefore relevant from both medical and aesthetic perspectives.

Methods: Two volunteer subjects were treated with a medical 20 MHz high intensity focused ultrasound device developed for dermatological conditions. One patient was given three treatments to remove a superficial congenital hemangioma on the left middle cheek. The other patient was given a single treatment to remove seven cherry angiomas on the thighs. Handpieces with nominal focal depths of 0.8 - 1.8 mm below the skin surface were used to administer acoustic energy of 1.1 - 1.2 J/dose. An integrated dermoscope in the handpiece was used to monitor the treatment in real-time.

Results: During treatment, blood in the capillary network of the lesions was coagulated immediately, and capillary walls were collapsed due to the thermal and mechanical effects of the high intensity focused ultrasound. During the healing phase, the areas regenerated a normal skin structure with very limited scar or dyspigmentation. At follow-up, a clear aesthetic improvement was observed over the baseline for all treated targets with the exception of two cherry angiomas, where focal depth and/or dose coverage had not been optimal.

Conclusion: High intensity focused ultrasound is concluded to be a safe and efficient skin treatment for benign superficial vascular malformations and tumors.

Keywords: HIFU; cherry angioma; congenital hemangioma; dermatology; focused ultrasound; vascular tumor.

Conflict of interest statement

The authors have no conflicts of interest to declare.

© 2021 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.

Figures

FIGURE 1
FIGURE 1
TOOsonix System ONE‐M. 20 MHz HIFU is transmitted to target lesions in the epidermis and dermis of the skin. The system has an integrated high‐resolution color dermoscope that allows real‐time control of the treatment
FIGURE 2
FIGURE 2
Congenital hemangioma on right cheek. (A): Photograph showing location of two closely spaced lesions. (B): Dermoscope picture of section in upper lesion showing a very fine capillary network connecting evenly distributed and round junctions of slightly larger capillary widening
FIGURE 3
FIGURE 3
Upper (A) and lower (B) region of congenital hemangioma directly after HIFU Treatment. The two treatment sessions are 2 weeks apart. Whitening and edema can be observed at the location of each HIFU dose. An urticarial “wheal and flare” response in the general surrounding area can be observed
FIGURE 4
FIGURE 4
Congenital hemangioma 15 weeks after first HIFU treatment. (A): Photograph showing treated area with decreased visual redness of area and generally good aesthetic result. (B): Dermoscope picture of section in upper lesion showing strongly decreased capillary network and hardly visible round junctions in the primary treatment area
FIGURE 5
FIGURE 5
Distribution of seven cherry angiomas selected for treatment by HIFU
FIGURE 6
FIGURE 6
Example of dermoscope pictures from successful removal of Cherry Angioma Number 4. (A): Before HIFU treatment. (B): Immediately after HIFU treatment. (C): 6 months after HIFU. (D): 12 months after HIFU treatment. A full removal without fibrotic tissue, remanent capillary network, or de‐pigmentation can be observed
FIGURE 7
FIGURE 7
Example of dermoscope pictures from successful removal of Cherry Angioma Number 1. (A): Before HIFU treatment. (B): Immediately after HIFU treatment. (C): 6 months after HIFU treatment. (D): 12 months after treatment. A full removal of the angioma with minimal fibrotic change and no remanent capillary network or de‐pigmentation can be observed
FIGURE 8
FIGURE 8
Example of dermoscope pictures from partially successful removal of Cherry Angioma Number 5. (A): Before HIFU treatment. (B): Immediately after HIFU treatment. (C): 6 weeks after HIFU treatment. (D): 12 months after HIFU treatment. A full removal with, but with some fibrotic change and de‐pigmentation can be observed
FIGURE 9
FIGURE 9
Example of dermoscope pictures from unsuccessful removal of Cherry Angioma Number 2. (A): Before HIFU treatment. (B): 6 months after HIFU treatment. (C): 12 month after HIFU treatment. A partial reduction of the angioma can be observed, but parts of the original angioma has regenerated a capillary network and is supplied with fresh blood. The capillaries can be observed to be relatively deep and course, and the original HIFU treatment has thus not been sufficiently deep and densely administered
FIGURE 10
FIGURE 10
Example of dermoscope pictures from unsuccessful removal of Cherry Angioma Number 6. (A): Before HIFU treatment. (B): 6 months after HIFU treatment. (C): 12 months after HIFU treatment. A reduction in the size and capillary network can be observed, but the angioma has regenerated most capillary network and the soft tissue and is supplied with fresh blood
FIGURE 11
FIGURE 11
Macroscopic photographs. (A): Before HIFU treatment. (B): 12 months after HIFU treatment. Five of the seven cherry angiomas are not clinically visible. Two cherry angiomas (number 2 and 6) have been reduced in sized but are still clearly visible and would need re‐treatment to be fully removed

References

    1. Pariser RJ. Benign neoplasms of the skin. Med Clin North Am. 1998;82(6):1285‐1307.
    1. James WD, Berger TG, Elston DM, (editors). Andrews Diseases of the Skin. 12th ed. Elsevier; 2016.
    1. Nasseri E, Piram M, McCuaig CC, Kokta V, Dubois J, Powell J. Partially involuting congenital hemangiomas: a report of 8 cases and review of the literature. Am Acad Dermatol. 2014;70(1):75‐79.
    1. Léauté‐Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85‐94.
    1. Holland KE, Drolet BA. Infantile Hemangioma. Pediatr Clin N Am. 2010;57:1069‐1083.
    1. Betz‐Stablein B, Koh U, Edwards HA, McInerney‐Leo A, Janda M, Soyer HP. Anatomic distribution of cherry angiomas in the general population. Dermatology. 2021;1‐9. Online ahead of print.
    1. Cheng J, Liu B, Lee HJ. Outcomes of surgical treatment for hemangiomas. Pediatr Dermatol. 2019;36:207‐212.
    1. Buslach N, Foulad DP, Saedi N, Mesinkovska NA. Treatment modalities for cherry angiomas: a systematic review. Dermatol Surg. 2020;46(12):1691‐1697.
    1. Vivar KL, Kruse L. The impact of pediatric skin disease on self‐esteem. Int J Womens Dermatol. 2018;4:27‐31.
    1. Focused Ultrasound Foundation . State of the field 2020. . Accessed October 6th.
    1. Ellens NPK, Partanen A. Preclinical MRI‐guided focused ultrasound: a review of systems and current practices. IEEE Trans Ultrason Ferroelectr Freq Control. 2017;64(1):291‐305.
    1. Barile A, Arrigoni F, Zugaro L, et al. Minimally invasive treatments of painful bone lesions: state of the art. Med Oncol. 2017;34(4):53.
    1. Kim M, Jung NY, Park CK, Chang WS, Jung HH, Chang JW. Comparative evaluation of magnetic resonance‐guided focused ultrasound surgery for essential tremor. Stereotact Funct Neurosurg. 2017;95(4):279‐286.
    1. Ellens N, Hynynen K. Frequency considerations for deep ablation with high‐intensity focused ultrasound: a simulation study. Med Phys. 2015;42(8):4896‐4910.
    1. Ko EJ, Hong JY, Kwon TR, et al. Efficacy and safety of non‐invasive body tightening with High‐Intensity Focused Ultrasound (HIFU). Skin Res Technol. 2017;23:558‐562.
    1. Day D. Microfocused ultrasound for facial rejuvenation: current perspectives. Res Rep Focus Ultrasound. 2014;2:13‐17. 10.2147/RRFU.S49900
    1. Park JH, Lim SD, Oh SH, Lee JH, Yeo UC. High‐intensity focused ultrasound treatment for skin: ex vivo evaluation. Skin Res Technol. 2017;23:384‐391.
    1. Bove T, Zawada T, Serup J, Jessen A, Poli M. High‐frequency (20‐MHz) High‐Intensity Focused Ultrasound (HIFU) system for dermal intervention: preclinical evaluation in skin equivalents. Skin Res Technol. 2019;25(2):217‐228.
    1. Soegaard S, Aarup V, Serup J, et al. High frequency (20 MHz) High Intensity Focused Ultrasound (HIFU) system for dermal intervention: a 12 week local tolerance study in minipigs. Skin Res Technol. 2020;26(2):241‐254.
    1. Serup J, Bove T, Zawada T, Jessen A, Poli M. High frequency (20 MHz) High‐Intensity Focused Ultrasound (HIFU): treatment of actinic keratosis, basal cell carcinoma and Kaposi sarcoma. Skin Res Technol. 2020;26:824‐831.
    1. TOOsonix A/S Denmark . System ONE‐M product brochure. . Accessed October 6th 2021.
    1. Bove T, Zawada T, Jessen A, Poli M, Serup J. Removal of common warts by high‐intensity focused ultrasound: an introductory observation. Case Rep Dermatol. 2021;13:340‐346.
    1. Serup J, Bove T, Zawada T, Jessen A, Poli M. High‐frequency (20 MHz) High‐Intensity Focused Ultrasound: new ablative method for color‐independent tattoo removal in 1–3 sessions. An open‐label exploratory study. Skin Res Technol. 2020;26:839‐850.

Source: PubMed

3
订阅